Innovations for Changing the Face of Women’s Reproductive Health Therapeutics

At ObsEva, our passion and expertise in reproductive health and pregnancy therapeutics is helping millions of women worldwide lead healthier and more fulfilling lives.

Nolasiban set to revolutionise fertility

Interview in ‘The Times’ with ObsEva CEO, Ernest Loumaye

Innovation From Conception to Birth and Beyond

ObsEva is advancing a robust pipeline of novel, orally-administered, clinical-stage compounds in the areas of uterine fibroids, endometriosis, assisted reproductive technology, and preterm labor.

Recent Updates

04 Jun 2019

ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes

Read more
16 May 2019

ObsEva SA to Participate in Upcoming Investor Conferences

Read more
09 May 2019

ObsEva Reports First Quarter 2019 Financial Results

Read more
09 May 2019

ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe

Read more